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ABSTRACT
BACKGROUND AND PURPOSE: Prediction of survival in patients with glioblastomas is important for individualized treatment planning.
This study aimed to assess the prognostic utility of presurgical dynamic susceptibility contrast and diffusion-weighted imaging for overall
survival in patients with glioblastoma.
MATERIALS AND METHODS: MR imaging data from pathologically proved glioblastomas between June 2006 to December 2013 in 58
patients (mean age, 62.7 years; age range, 22–89 years) were included in this retrospective study. Patients were divided into long survival
(15 months) and short survival (15 months) groups, depending on overall survival time. Patients underwent dynamic susceptibility
contrast perfusion and DWI before surgery and were treated with chemotherapy and radiation therapy. The maximum relative cerebral
blood volume and minimum mean diffusivity values were measured from the enhancing part of the tumor.
RESULTS: Maximum relative cerebral blood volume values in patients with short survival were significantly higher compared with those
who demonstrated long survival (P .05). No significant differencewas observed in theminimummean diffusivity between short and long
survivors. Receiver operator curve analysis demonstrated that a maximum relative cerebral blood volume cutoff value of 5.79 differen-
tiated patients with low and high survival with an area under the curve of 0.93, sensitivity of 0.89, and specificity of 0.90 (P .001), while
aminimummean diffusivity cutoff value of 8.35 104mm2/s had an area under the curve of 0.55, sensitivity of 0.71, and specificity of 0.47
(P .05) in separating the 2 groups.
CONCLUSIONS: Maximum relative cerebral blood volume may be used as a prognostic marker of overall survival in patients with
glioblastomas.
ABBREVIATIONS: EGFR epidermal growth factor receptor; GBM glioblastoma; MDmean diffusivity; MDminminimum mean diffusivity; rCBV relative
cerebral blood volume; rCBVmax maximum relative cerebral blood volume
Glioblastomas (GBMs) are the most common malignant tu-mors of the central nervous system in adults, representing
50% of all gliomas and 20% of all intracranial solid lesions.1 The
prognosis of GBM is poor, and median overall survival is 1
year.2 Even in optimal conditions (young patients treated by rad-
ical surgery, radiation therapy, and chemotherapy), death usually
occurs within 2 years.3,4 Several factors, both clinical (age, perfor-
mance status) and therapeutic (extent of surgery, radiation ther-
apy, chemotherapy), as well as specific tumor characteristics such
as location and nature (de novo or secondary from a low-grade
glioma)5,6 have been studied as potential prognostic markers of
overall survival with variable degrees of sensitivity and specificity.
Recently, tumor genetics is also being investigated as a prognostic
index.7,8
Conventional MR imaging is widely used as the technique of
choice for GBMdiagnosis and also has an important role inmon-
itoring disease progression and response to therapy for patients
with GBM. Additional advanced imaging techniques, such as rel-
ative cerebral blood volume (rCBV) obtained from dynamic sus-
ceptibility contrast perfusion imaging, have been used to predict
glioma grade9-11 and assess treatment response.12 A recent re-
port10 indicated that maximum relative cerebral blood volume
(rCBVmax) can be used as a predictive marker of progression-free
survival in patients with gliomas, regardless of the tumor grade.
Similar to perfusion imaging, diffusion-weighted imaging has
also been used for diagnosis of tumors. Tumors with high cellu-
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larity demonstrate restricted diffusion and thus low mean diffu-
sivity (MD)or apparent diffusion coefficient, which inversely cor-
relates with tumor cellularity.13,14 Areas with minimum mean
diffusivity (MDmin) reflect the sites of highest cellularity, and tu-
mors with a low MD tend to have a poor prognosis.15-18
Radiation therapy and chemotherapy with temozolomide
have become the standard of care in the treatment of GBM and
have demonstrated increased survival benefits in patients with
newly diagnosed GBM.19 However, several clinical trials, includ-
ing blocking the tyrosine kinase activity of epidermal growth fac-
tor receptor (EGFR),20,21 using competitive and noncompetitive
kinase inhibitors in combination with radiation and temozolo-
mide,20,21 and usingmonoclonal antibodies,20 are also investigat-
ing the treatment of GBMs. The exact value of each of these ther-
apeutic strategies remains investigative though. The overall
survival of patients with glioblastomas varies significantly,17,18
and it is imperative to knowwhich patientswill do better orworse,
preferably before initiation of treatment, by using a noninvasive
imaging method, so as to tailor fit the therapy for the best man-
agement and hopefully increased survival. We have evaluated the
role of DSC-MR imaging and DWI as potential prognostic imag-
ing markers in patients with GBM with an eventual goal of using
these parameters in the selection of the optimal treatment option
for these patients.
MATERIALS AND METHODS
MR Imaging
This retrospective study was approved by the institutional review
board and was compliant with the Health Insurance Portability
and Accountability Act. A total of 564 treatment-naïve patients
diagnosed with GBM at the University of Pennsylvania from June
2006 to December 2013 were retrospectively reviewed. Because
we were interested in evaluating the role of perfusion-weighted
imaging anddiffusion-weighted imaging,we excluded the cases in
which the PWI or DWI scans were not available. In addition, we
analyzed the pretreatment MR imaging scans of only those pa-
tients who had gross total resection of their tumors so that the
extent of surgery was not a confounder in the analysis. Further-
more, we also excluded all GBMs with oligodendroglial features.
Of the 564 cases reviewed, 58 patients (32 men and 26 women;
mean age, 62.71  13.2 years; age range, 22–89 years) with a
pathologically proved GBM met our inclusion criteria and were
included in the study. After surgery, all the patients were treated
with chemotherapy and radiation therapy.
We used a 15-month overall survival as the cutoff to evaluate
rCBVmax andMDmin as predictive markers because several previ-
ous studies have reported a median overall survival time of 12–15
months for patients with GBM.2,18,19 Thus, the 58 patients in our
study were divided into 2 groups: patients having long survival
(n 30, patients who had an overall survival of15months) and
short survival (n 28, patientswhohad anoverall survival of15
months). The survival timewas calculated as the time (inmonths)
from the initial date of diagnosis until the date of death. The
clinical symptoms, survival duration, Karnofsky score, and lesion
diameter of the patients demonstrating short and long survival are
reported in On-line Tables 1 and 2. The MR images acquired
before surgery (1 week) were evaluated in this study.
All MR images were obtained on a 3T clinical MR imaging
system (TimTrio; Siemens, Erlangen, Germany), equippedwith a
12-channel phased array head coil. The imaging protocol in-
cluded a 3-plane scout localizer, axial 3D T1-weighted magneti-
zation-prepared rapid acquisition of gradient-echo images by us-
ing the following parameters: TR, 1760ms; TE, 3.1ms; TI, 950ms;
matrix size, 192  256; FOV, 25  25 cm2; and 1-mm section
thickness; and FLAIR images with TR, 9420 ms; TE, 141 ms; TI,
2500 ms; matrix size, 192  256; and 3-mm thick contiguous
sections with no gap. DWI data were acquired by using a single-
shot spin-echo echo-planar imaging sequence with parallel imag-
ing by using a generalized autocalibrating partially parallel acqui-
sition and an acceleration factor of 2. Other sequence parameters
were as follows: FOV 22 22 cm2; b0, 1000 s/mm2; section
thickness, 3 mm; number of sections, 40; acquisition time, 8
minutes.
For dynamic susceptibility contrast imaging, a bolus of gado-
benate dimeglumine (MultiHance; Bracco Diagnostics, Prince-
ton, New Jersey) was injected as the preloading dose of 0.07
mmol/kg. The preloading dose was administered to reduce the
effect of contrast agent leakage on CBV measurements. A DSC
T2*-weighted gradient-echo, echo-planar sequence was obtained
during the second 0.07-mmol/kg bolus of intravenous contrast
agent. The injection rate was 5 mL/s for all patients and was im-
mediately followed by a bolus injection of saline (total of 20mL at
the same rate). DSC sequence parameters included the following:
TR/TE, 2000/45 ms; FOV, 22  22 cm2; in-plane resolution,
1.72  1.72  3 mm3; slab of 20 sections covering the tumor
region; and acquisition time of 1 minute 38 seconds. A long TR
and a low flip angle were used to reduce the effect of changes in T1
relaxation from contrast agent leakage.22 Post-contrast-enhanced
T1-weightedMPRAGE images were acquired after completion of
the DSC sequence.
Image Processing
The rCBV was calculated from PWI data by using the intravascu-
lar indicator dilution algorithms described previously.23-25 Data
processing was performed by using PWI Task Card (Massachu-
setts General Hospital, Boston, Massachusetts) on a Leonardo
workstation (Siemens). MD maps were automatically generated
by using the software tools available on the scanner by using a
monoexponential fit to the multiple b-value images. Measure-
ments were obtained by 2 radiologists (G.C¸. and F.K., with 4
years of experience reading brain MR imaging). We meticulously
chosemultiple ROIs from the enhancing part of the tumor, avoid-
ing areas of cerebral blood vessels, calcifications, hemorrhage, and
CSF-filled sulci to measure a reliable CBV value as proposed ear-
lier.26-27 The ROIs were drawn and chosen in agreement by the 2
readers, thereby reducing any interobserver variability. The com-
monly used rCBVmax parameter
28 was computed by calculating
themeanCBVvalues from3 circular ROIsmeasuring 30–50mm2
from areas of visually high CBV as reported previously.26-27 For
normalization, 3 circular ROIs of the same size were drawn in the
contralateral normal-appearing white matter. A similar analysis
method was used to investigate the minimum mean diffusivity.
Three circular ROIsmeasuring 30–50mm2 from the visually low-
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est MD values were used to compute MDmin, representing high
cellularity as reported previously.13,17
Statistical Analysis
The long and short survival patient groups were compared by
using a Student t test. A P value .05 was considered significant.
A receiver operating characteristic analysis was performed to eval-
uate the predictive power of rCBVmax andMDmin for overall sur-
vival. Areas under the curve were computed. A cutoff value for
each parameter was determined by maximizing the sum of sensi-
tivity and specificity. Kaplan-Meier survival curves were used to
characterize and compare the groups with high-versus-low rCBVmax
and high-versus-low MDmin in terms of overall survival. All sta-
tistical analyses were conducted by using PASW Statistics, Ver-
sion 18 (IBM, Armonk, New York).
RESULTS
Representative images of patients with GBM with long and
short survival are shown in Fig 1. The contrast-enhanced T1-
weighted images and FLAIR images from these patients look
similar, showing heterogeneous peripheral enhancement and
extensive surrounding FLAIR signal abnormality. All tumors
showed prominent enhancement after IV contrast administra-
tion. The patient with short survival demonstrated higher
rCBVmax compared with the patient who exhibited long
survival.
The rCBVmax values of patients with short survival (9.90 
4.01) were significantly higher compared with those of long sur-
vival (4.78 1.30, P .05). There was no significant difference in
theMDmin values between the 2 groups: 0.80 0.17 versus 0.75
0.15 103mm2/s (Table).
Receiver operating characteristic analysis indicated that a
rCBVmax cutoff value of 5.79 was the best parameter for predict-
ing overall survivalwith an area under the curve of 0.93, sensitivity
of 0.89, specificity of 0.90, positive predictive value of 0.89, and
negative predictive value of 0.90 (Fig 2 and Table). The MDmin
cutoff value of 8.35  104mm2/s, on the other hand, showed
only a modest area under the curve of 0.55, sensitivity of 0.71,
specificity of 0.47, positive predictive value of 0.56, and negative
predictive value of 0.64 (Fig 2 and Table). A combination of rCB-
Vmax and MDmin did not improve the prediction capability and
had an area under the curve (0.93) similar to that of rCBVmax.
Kaplan-Meier survival curves demonstrated that GBMs with low
rCBVmax (5.79) had amedian survival time of 23 3.4months,
whereas GBMswith high rCBVmax (5.79) had amedian survival
time of 5 1.9 months (Fig 3). There was a significant difference
in patients with high rCBVmax and low
rCBVmax (P .001). For the DWI mea-
surements, GBMs with low MDmin
(8.35  104mm2/s) had a median
survival time of 14  2.0 months,
whereas GBMs with high MDmin
(8.35 104mm2/s) had amedian sur-
vival time of 18 1.4 months, and there
was no significant difference between
the 2 groups (P .05) (Fig 4).
DISCUSSION
Our study suggests that pretreatment
rCBVmax can be used as a prognostic
marker for overall survival in patients
with GBM. In particular, patients with
high pretreatment rCBVmax demon-
strated lower survival in comparison
with patients with low pretreatment
rCBVmax, who exhibited longer survival
of15months. These results could have
a potential clinical benefit and in the
future may aid in individualized treat-
ment planning because patients with
high pretreatment rCBVmax can be of-
fered upfront alternative treatment
FIG 1. Representative MR images and parametric maps from patients with GBM. The top row
(A–D) shows images from a 66-year-old woman with GBM who survived for 58 months after
gross total resection of her GBM in the left temporo-occipital lobe. Representative MR images
from a 75-year-old man with a GBM in the left parietal lobe with only a 5-month survival are
shown (E–H). Images of both patients demonstrate heterogeneous peripheral enhancement (A
and E) and extensive surrounding FLAIR signal abnormality (B and F) on axial contrast-enhanced
T1-weighted and FLAIR images, respectively. The patient with short survival has a higher CBV (G)
(rCBVmax 12.22) in comparison with the patient with long survival (C) (rCBVmax 3.57). The MD
maps from these patients (D andH) do not show any difference (6.50 104mm2/s versus 6.80
104 mm2/s).
Average SD, sensitivity, specificity, PPV, and NPV of pretreatment rCBVmax and MDmin in patients with GBM demonstrating long
(>15 mo) survival and short (<15 mo) survival
Long Survival (n = 30) Short Survival (n = 28)
Cutoff AUC Sensitivity Specificity PPV NPVMean SD Mean SD
rCBVmax 4.78 1.30 9.90 4.01
a 5.79 0.93 0.89 0.90 0.89 0.90
MDmin (10
3mm2/s) 0.80 0.17 0.75 0.15 0.83 0.55 0.71 0.47 0.56 0.64
Note:—NPV indicates negative predictive value; PPV, positive predictive value; AUC, area under the curve.
a P .01.
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strategies, including bevacizumab, immunotherapy, or other
therapies targeted toward increased survival.
Conventional imaging characteristics of GBM, including loca-
tion, size, and degree of enhancement; necrosis; and extent of
edema, have been studied for prediction of survival.9-11,29-36 Al-
though contrast enhancement is generally used to estimate the
extent of the tumor, it is clear from the literature that conven-
tional radiologic findings, such as the absence of contrast en-
hancement, are not only poor predictors of tumor grade but may
or may not be prognostic factors for either survival or progres-
sion-free survival.12,37 PWI is increasingly being used to assess
microvascular changes associated with the tumor grade, and it is
widely used to assess tumor angiogenesis and microvascula-
ture.34,35,38 Law et al30 suggested that rCBV measurements in
low-grade gliomas correlated more accurately with time to pro-
gression than the initial histopathologic grading of the tumor.
Although Oh et al18 suggested that rCBV had no predictive value
with respect to the prognosis in GBM, they evaluated GBM tu-
mors after surgical resection; thus, it is unclear whether the extent
of surgery played a role in determining the prognostic value in
their study.18 Bisdas et al11 reported that there was no correlation
amongCBV,WorldHealthOrganization grade, and progression-
free survival in a mixed population of gliomas. Similar to ours,
findings of Mangla et al32 were that rCBV was useful for predict-
ing progression-free survival in anaplastic astrocytomas, but not
for grade III tumors with oligodendroglial components.
We observed that an rCBVmax threshold value of 5.79 was the
best predictor for overall survival with a very high sensitivity and
specificity. In other words, this threshold was evaluated as a prog-
nostic index of survival in GBM and not for predicting tumor
grade, for which a much lower rCBV threshold was reported by
Bisdas et al11 (4.2), Lev et al29 (1.5), Law et al31 (1.75), andMangla
et al32 (2.55).
High-grade brain tumors are usually associated with high cel-
lularity and therefore exhibit low MD values.15-17 Previous stud-
ies15,16,39 reported that MDmin was a sensitive marker for prog-
nosis and survival. The cutoff MD values used in these studies
were 0.74  103 mm2/s, 0.90  103 mm2/s, 0.93  103
mm2/s, and 1.00 103 mm2/s, respectively.15-18 Higano et al16
studied 37 malignant astrocytic tumors, including 22 GBMs, and
reported a significant negative correlation between MDmin and
FIG 2. Receiver operative characteristic curves of rCBVmax (solid line)
by using a rCBVmax cutoff value of 5.79. The area under the curve was
0.93. The receiver operating curve of MDmin (dotted line) by using a
cutoff value of 8.35 104mm2/s demonstrated only a modest area
under the curve of 0.55.
FIG 3. Kaplan-Meier curves for patients with low (5.79, solid line)
and high (5.79, dotted line) rCBVmax. GBMs with low rCBVmax had a
median survival time of 23  3.4 months, whereas GBMs with high
rCBVmax had a median survival time of 5 1.9 months (P .001). Cum
indicates cumulative.
FIG 4. Kaplan-Meier curves for patients with GBM with low
(0.835  103mm2/s, solid line) and high (0.835  103mm2/s,
dotted line) MDmin. GBMs with a low MDmin have a median survival
time of 14  2.0 months, whereas GBMs with a high MDmin have a
median survival time of 18 1.4 months. There is no significant differ-
ence between the 2 groups (P .05). Cum indicates cumulative.
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Ki-67, which may explain the poor prognosis of patients with
lower MDmin. The authors of that study also reported that the
MDmin (0.834  10
3mm2/s) of GBM was significantly lower
than theMDmin (1.06 10
3mm2/s) of anaplastic astrocytomas.
In another study, Murakami et al15 studied 79 malignant supra-
tentorial astrocytic tumors, including 50 patients withGBMs, and
observed that patients with an MDmin of 1.00  10
3mm2/s
had better outcomes than patients with an MDmin of 1.00 
103mm2/s. Yamasaki et al39 reported that MDmin also predicted
overall survival in patients with GBMs who did not have a com-
plete- or near-total resection of their tumors. We did not observe
an MDmin cutoff value that could differentiate patients having
short or long survival (Fig 4). However, in comparison with these
previous studies, we studied a homogeneous population of pa-
tients with GBMs who had undergone gross total resection of
their tumors, which may partially explain the difference in our
results.
Because GBM is composed of prominent necrosis, nuclear
atypia, cellular proliferation, and microvascular hyperplasia, the
extent of necrosis and the amount of edema have been shown to
negatively correlate with survival.5,40 Immunohistochemical
staining for p53, Ki-67, and EGFR is generally used for differential
diagnosis and grading of these tumors.41 Previous studies have
shown that abnormal microvasculature may be associated with
increased endothelial cellularity, proliferation, and tumor
grade.42,43 Tumors with increased EGFR, Ki-67, and p53 staining
are more invasive and exhibit a more malignant phenotype. A
tumor-specific mutant of the EGFR, EGFRvIII, causes constitu-
tive upregulation of the tyrosine kinase activity of the receptor
and is frequently expressed in primary GBMs. EGFR signaling
has, therefore, been the target for GBM therapy. It is also possible
that rCBV measurements are revealing changes in microvascular
attenuation that precede malignant transformation44 and may be
indicative of poor prognosis as demonstrated in our study.
Previous survival analysis studies for patients with brain tu-
mors have evaluated several factors: tumor grade, extent of resec-
tion, radiation dose, age, and Karnofsky score.5,6 Based on the
results of some prospective clinical trials that evaluated patients
with gliomas, the important prognostic factors for predicting out-
come in gliomas are the extent of surgical resection, histologic
results, and size of the lesion.12,45,46 Tumors not involving elo-
quent regions of the brain undergo gross total resection because it
has been shown that maximal resection improves survival in pa-
tients with gliomas.12,45,46 Preoperative knowledge of the
rCBVmax of a tumor may help to determine whether to biopsy or
to resect, the aggressiveness of resection, the use of pre-/postop-
erative adjuvant radiation therapy and chemotherapy, and the
frequency of follow-up examinations.
Although our study indicates the role of pretreatment
rCBVmax as a potential imaging biomarker for predicting survival
in GBM, the results should be interpreted in light of the limita-
tions of the study. One was the use of hand-drawn ROIs for data
analysis, which, though being simple and straightforward, tend to
be subjective. Future studies involving semiautomated segmenta-
tion routines47,48 may be needed to analyze the data more objec-
tively without any user bias. In addition, we did not evaluate other
perfusion variables from the DSC data, such as cerebral blood
flow andmean transit time values. Increasing the TR is only one of
themethods to reduce the effects of T1, but it comeswith a penalty
of increased acquisition time. In addition to the simplistic mea-
surements of MDmin, other parameters from diffusion imaging
can be computed, such as fractional anisotropy and radial and
axial diffusivity. It would be desirable to perform a multivariate
analysis by using these varied imaging parameters to evaluate
whether these additional parameters further increase the sensitiv-
ity and specificity in the overall prognosis of patients with GBM.
The study was performed retrospectively, and the sample size for
the Kaplan-Meier analysis was relatively small. The survival of
patients withGBMcan also be affected by other factors such as the
location, tumor size, and Karnofsky score. A larger sample size
would be necessary to perform a Kaplan-Meier analysis of the
rCBVmax accounting for these confounding factors.We have lim-
ited the number of confounders, including selection of pureGBM
(excluding patients with oligodendroglial features) and selection
of patients with near-total resection of themass, and restricted the
analysis to tumors with a similar initial size in the 2 groups. A
prospective study on a larger cohort of patients with GBM needs
to be performed to further establish rCBV as a marker for overall
survival in GBM.
CONCLUSIONS
Our results indicate that pretreatment rCBVmax may be a used as
a sensitive prognostic marker for overall survival in patients with
glioblastomas.
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